AXIM Biotechnologies, Inc.
AXIM · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.03 | 0.01 | 0.01 |
| FCF Yield | -33.63% | -10.59% | -12.88% | -17.36% |
| EV / EBITDA | 29.07 | -163.07 | -33.90 | -24.24 |
| Quality | ||||
| ROIC | 10.08% | 8.26% | 11.48% | 13.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -4.96 | 0.57 | 0.19 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 2.41% | 99.49% | 138.74% |
| Free Cash Flow Growth | -406.23% | -70.53% | 70.33% | -147.55% |
| Safety | ||||
| Net Debt / EBITDA | 22.97 | -139.34 | -31.06 | -19.93 |
| Interest Coverage | -3.44 | -3.67 | -3.81 | -5.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,494.55 | 0.00 | -1,387.59 | -1,490.35 |